Clinical Trials
3 trialsNCT02223208 2025-12-02
FIL_PTCL13
Fondazione Italiana Linfomi - ETS
Phase 1/2 Active not recruiting
NCT05429905 2023-03-09
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
KK Women's and Children's Hospital
Phase 1/2 Unknown
NCT01572519 2020-11-20
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1 Completed